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Abstract:  Nanotechnology,  along  with  related  concepts  such  as  nanomaterials, 
nanostructures and nanoparticles, has become a priority area for scientific research and 
technological development. Nanotechnology, i.e., the creation and utilization of materials 
and devices at nanometer scale, already has multiple applications in electronics and other 
fields.  However,  the  greatest  expectations  are  for  its  application  in  biotechnology  and 
health, with the direct impact these could have on the quality of health in future societies. 
The emerging discipline of nanomedicine brings nanotechnology and medicine together in 
order to develop novel therapies and improve existing treatments. In nanomedicine, atoms 
and molecules are manipulated to produce nanostructures of the same size as biomolecules 
for  interaction  with  human  cells.  This  procedure  offers  a  range  of  new  solutions  for 
diagnoses and ―smart‖ treatments by stimulating the body‘s own repair mechanisms. It will 
enhance  the  early  diagnosis  and  treatment  of  diseases  such  as  cancer,  diabetes, 
Alzheimer‘s,  Parkinson‘s  and  cardiovascular  diseases.  Preventive  medicine  may  then 
become a reality. 
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1. Introduction  
The  term  nanotechnology  refers  to  the  ability  to  measure,  design  and  manipulate  materials  at 
atomic, molecular and supramolecular level in order to understand, create and apply structures and 
systems with specific functions attributable to their size. Nanotechnology classically refers to matter in 
the size range of 1–100 nm, but it is often extended to include materials below 1 µm in size. A key 
goal is to assemble nanoparticles and integrate them into ordered structures in order to obtain useful 
materials. Although new, the advent of nanomaterials was forecast as long ago as 1959 by Richard P.  
Feynman [1]. Nanotechnology has been embraced by multiple industrial sectors for application in the 
field of electronic storage systems [2], biotechnology [3], magnetic separation and preconcentration of 
target analytes and targeted drug delivery [4,5], and as vehicles for gene and drug delivery [2,4,5]. 
Advances in nanotechnology have led to the development of new nanomaterials whose physiochemical 
properties differ from those of their larger counterparts due to their higher surface-to-volume ratio. 
These novel properties make them excellent candidates for biomedical applications, given the range of 
biological processes that occur at nanometer scale [6]. Nanotechnology is a new discipline of science 
and engineering that has led to innovative approaches in many areas of medicine. Its applications in the 
screening,  diagnosis,  and  treatment  of  disease  are  collectively  referred  to  as  ―nanomedicine‖—an 
emerging  field  that  has  the  potential  to  revolutionize  individual  and  population-based  health  this 
century [7]. It is now possible to provide therapy at a molecular level with the help of nanoparticles, 
treating  diseases  and  adding  to  our  understanding  of  their  pathogenesis.  Nanomedicine  can  be 
considered a refinement of molecular medicine, integrating innovations in genomics and proteomics on 
the road to a more personalized medicine. 
The impact of nanotechnology in medicine can mainly be seen in diagnostic methods, drug-release 
techniques and regenerative medicine.  
Diagnostic  methods  are  essential  for  the  early  detection  of  diseases  to  enable  their  prompt 
treatment,  minimizing  possible  damage  to  the  rest  of  the  organism.  The  importance  of  imaging 
methods  to  diagnose,  treat  and  follow  up  cancer,  cardiovascular  and  neurological  patients  is  well 
known. Diagnostic techniques based on the use of nanoparticles offer higher sensitivity and assist the 
early  detection  of  disease,  offering  a  better  prognosis  and  greater  possibilities  of  successful  
treatment [8]. Once the diagnosis is established, the fight against the disease begins, with medicaments 
playing a major role. There are numerous obstacles to the development of novel drugs against disease. 
Conventional drugs suffer from the major limitation of adverse effects, the result of the non-specificity 
of their action, and from a lack of effectiveness due to improper or ineffective dosages, e.g., in cancer 
chemotherapy  and  anti-diabetic  therapy.  Nanotechnology  offers  the  possibility  of  designing  novel 
drugs with greater cell specificity and new drug-release systems that act selectively on specific targets 
and protect the drug from degradation en route. This allows the administration of smaller but more 
effective  doses,  minimizing  adverse  effects.  Nanotechnology  can  also  be  used  to  optimize  drug 
formulations, increasing drug solubility and altering the pharmacokinetics to sustain the release of the 
drug, thereby prolonging its bioavailability. The diverse platforms of nanotechnology can be utilized to 
develop  more  sophisticated,  cell-targeted  therapies  and  to  combine  different  drugs  into  a  single 
nanotherapeutic agent for synergistic therapeutic benefits [9].  Int. J. Mol. Sci. 2011, 12                       
 
 
3305 
Regenerative  medicine  has  been  proposed  as  a  highly  promising  approach  to  numerous 
degenerative  diseases.  To  this  end,  nanomedicine  employs  gene  therapy,  cell  therapy,  tissue 
engineering, biomaterials and signaling molecules. 
2. Nanomedicine Applications 
Nanomedicine  applications  are  grouped  below  in  three  interrelated  areas:  analytical/diagnostic 
tools, drug delivery and regenerative medicine (Figure 1).  
Figure 1. Nanomedicine application areas.  
 
 
2.1. Analytical and Diagnostic Tools 
The limitations of current diagnostic technology mean that some diseases can only be detected 
when at a very advanced stage. Nanodiagnostics, defined
 as the use of nanotechnology for clinical 
diagnostic purposes [10,11], was developed to meet the demand for increased sensitivity in clinical 
diagnoses and earlier disease detection.
  
The application of micro and nanobiotechnology in medical diagnostics can be subdivided into two 
broad categories: In vitro diagnostic devices and in vivo imaging. Research in this field is highly  
multi-disciplinary and there are close relationships among diagnostics, drug release and regenerative 
medicine, which are described in the following sections.  
2.1.1. In Vitro Diagnostic Devices 
The grounds for modern medicine were already laid in the middle of the 19th century with the 
recognition  of  the  cell  as  the  source  of  health  and  disease.  Basic  research  to  yield  a  better 
understanding of the highly complex working of cells became mandatory in medicine. The resulting 
improvements  in  methods  to  characterize  cells  or  cell  compartments  in  vitro  (e.g.,  optical  and Int. J. Mol. Sci. 2011, 12                       
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luminescence  microscopy,  scanning  probe  microscopy,  electron  microscopy  and  imaging  
mass-spectrometry) have been critically important for the development of nanomedicine. 
The  miniaturization  and  integration  of  different  functions  in  a  single  device,  based  on 
nanotechnology-derived techniques, have led to a new generation of devices that are smaller, faster 
and cheaper, require no special skills and give accurate readings. They require much smaller samples, 
implying less invasive and traumatic sample extraction methods, and deliver more complete and more 
accurate biological data from a single measurement. The use of these devices in research has become 
routine and has improved our understanding of the molecular basis of disease and helped to identify 
new therapeutic targets. In vitro diagnostic devices include nanobiosensors, microarrays, biochips of 
different elements (DNA, proteins or cells) and lab-on-a-chip devices. 
2.1.1.1. Nanobiosensor 
A nanobiosensor is defined as a compact analysis device that incorporates biological (nucleic acid, 
enzyme, antibody, receptor, tissue, cell) or biomimetic (macrophage-inflammatory proteins, aptamers, 
peptide  nucleic  acids)  recognition  elements  [11,12].  Interaction  between  the  compound  or 
microorganism  of  interest  and  the  recognition  element  produces  a  variation  in  one  or  more  
physical-chemical properties (e.g., pH, electron transfer, heat, potential, mass, optical properties, etc.) 
that are detected by the transducer. The resulting electronic signal indicates the presence of the analyte 
of interest and its concentration in the sample. These sensors can be electronically gated to respond to 
the binding of a single molecule. Prototype sensors have been successfully used to detect nucleic acids, 
proteins  and  ions.  They  can  operate  in  liquid  or  gas  phase,  opening  up  an  enormous  variety  of 
downstream applications. These detection systems use inexpensive low-voltage measurement methods 
and detect binding events directly, so there is no need for costly, complicated and time-consuming 
chemical labeling, e.g., with fluorescent dyes, or for bulky and expensive optical detection systems. As 
a result, these sensors are inexpensive to manufacture and portable [10]. Hence, nanobiosensors are 
revolutionizing the in vitro diagnosis of diseases and have major implications for human health. They 
allow healthcare professionals to simultaneously measure multiple clinical parameters using a simple, 
effective and accurate test. These devices are also ideal for high-throughput screening and for the 
detection of a single disease in various samples or of various diseases in a single sample [13].  
2.1.1.2. Microarrays 
The microarray is another diagnostic device that is becoming a standard technology in research 
laboratories worldwide. Since their first application,
 microarray technologies have proven productively 
functional in almost all areas of biomedical research [14–21]. The emergence of this new tool has 
allowed  investigators  to  address  previously  intractable  problems  and  identify  novel  potential 
therapeutic targets. They are using microarray technology to identify cardinal aspects of growth and 
development  and  explore  the  underlying  genetic  causes  of  numerous  human  diseases  [14].  
Microarray-based studies have enormous potential in the exploration of diseases such as cancer
 [15] 
and in the design and development of new drugs [16]. Microarrays have been widely applied in the 
study  of  various  pathological  conditions,  including  inflammation  [17],  atherosclerosis  [18],  breast  Int. J. Mol. Sci. 2011, 12                       
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cancer [19,20], colon cancer [21] and pulmonary fibrosis [22]. As a result, functions have been assigned 
to previously unannotated genes, and genes have been grouped into functional pathways [23,24]. 
Several types of microarray have been developed for different target materials, which can be DNA, 
cDNA,  mRNA,  protein,  small  molecules,  tissues  or  any  other  material  that  can  be  quantitatively 
analyzed. DNA microarray technology has progressed rapidly over the past 10 years and allows the 
large-scale  quantification  of  gene  expression.  A  DNA  array  consists  of  a  large  number  of  DNA 
molecules orderly arranged on a solid substrate to form a matrix of sequences in two dimensions [25]. 
cDNA microarrays and oligonucleotide microarrays, called ‗expression chips‘, are used for microarray 
expression  analysis,  i.e.,  to  determine  the  level  or  volume  of  expression  of  a  given  gene.  Single 
nucleotide  polymorphism  (SNP)  microarrays  detect  mutations  or  polymorphisms  in  a  gene  
sequence [26]. This technology is used to test an individual for disease expression patterns and to 
determine whether or not individuals are susceptible to a disease. Microarray comparative genomic 
hybridisation [27] is employed to seek genomic gains and losses or changes in the number of copies of 
a  gene  implicated  in  a  disease.  Protein  microarrays  are  comprised  of  protein  detectors  (usually 
antibodies) arranged systematically over a glass slide and allow the investigation of expression profiles 
and  the  precise  definition  of  protein  functions  in  relation  to  biological  processes  [28].  Tissue 
microarrays represent one of the most valuable approaches in the microarray field, because they allow 
the simultaneous analysis of protein, RNA and DNA expression in multiple tissue samples [29]. 
The main applications of microarrays in human health are listed below [30]. 
- Gene expression analysis, used to determine gene expression patterns and simultaneously quantify 
the expression of a large number of genes, permitting comparison of their activation between healthy 
and diseased tissues. 
- Detection of mutations and polymorphisms, allowing the study of all possible polymorphisms and 
the detection of mutations in complex genes. 
- Sequentiation, used to sequence short DNA fragments (sequencing of long DNA fragments has 
not yet proven possible, although they can be used as quality controls). 
-  Therapy  follow-up,  allowing  evaluation  of  genetic  features  that  may  affect  the  response  to  a  
given therapy.  
- Preventive medicine, developing knowledge on the genetic features of diseases in order to treat 
and prevent them before symptom onset. 
- Drug screening and toxicology, analyzing changes in gene expression during the administration of 
a  drug,  as  well  as  localizing  new  possible  therapeutic  targets  and  testing  for  associated  
toxicological effects. 
- Clinical diagnosis, allowing the rapid identification of pathogens by employing the appropriate 
genetic markers. 
In  conclusion,  molecular  diagnosis  is  a  fast-growing  field.  Analysis  of  global  expression  by 
microarray techniques simultaneously reveals the state of thousands of genes of diseased cells. These 
approaches offer a more accurate diagnosis and risk assessment for various diseases, leading to a more 
precise prognosis and new therapeutic approaches. The ultimate reach of microarray technology will 
be achieved with its entry into the physician‘s clinic as a routine diagnostic tool [31]. Int. J. Mol. Sci. 2011, 12                       
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2.1.1.3. Lab-on-a-Chip 
The latest in vitro diagnostic development derives from the integration of several functions in a 
single device. Lab-on-a-chip integrates one or several laboratory functions on a single chip ranging 
from only a few millimeters to a square centimeter in size [32] and incorporates sample preparation, 
purification, storage, mixing, detection and other functions. Its development was based on advances in 
microsystem  technologies  and  in  the  field  of  microfluidics  on  the  design  of  devices  that  use 
microscopic  volumes  of  sample.  The  chips  use  a  combination  of  phenomena,  including  pressure, 
electroosmosis,  electrophoresis  and  other  mechanisms  to  move  samples  and  reagents  through 
microscopic channels and capillaries, some as small as a few dozen nanometers. 
Lab-on-a-chip has many applications in medicine and biology. These devices are likely to have a 
significant socio-economic impact, bringing sophisticated analytical tools to Third World countries, 
rural areas and resource-poor regions. Advantages of their use include the extremely rapid analysis of 
samples containing fluid volumes that can be less than a picoliter, the high degree of automation, cost 
savings due to the low consumption of reagents and samples and their portable and disposable nature. 
Lab-on-a-chip is used in real-time polymerase chain reaction [33] and immunoassays [34] to detect 
bacteria, viruses and cancers. It can also be used in blood sample preparation to crack cells and extract 
their DNA [32]. Lab-on-a-chip may soon play an important role in efforts to improve global health, 
especially with the development of point-of-care testing devices. Infectious diseases that are treatable 
in developed nations are often deadly in countries with limited healthcare resources. In some cases, 
healthcare clinics possess a drug to treat a given disease but lack the diagnostic tool to identify the 
patients who should receive it. Many researchers believe that lab-on-a-chip technology will be the key 
to  powerful  new  diagnostic  instruments.  The  goal  is  to  create  microfluidic  chips  that  will  allow 
healthcare providers in poorly-equipped clinics to perform diagnostic tests (e.g., immunoassays and 
nucleic  acid  assays)  with  no  laboratory  support.  One  active  research  line  on  the  lab-on-a-chip 
addresses  the  diagnosis  and  management  of  HIV  infections  [35].  Around  40  million  people  are 
infected with HIV in the world, yet only 1.3 million receive antiretroviral treatment and around 90% of 
HIV-infected individuals have never been tested for the disease. This is largely because its diagnosis 
requires  measurement  of  the  number  of  CD4+  T  lymphocytes  in  the  blood  by  means  of  flow 
cytometry, a complicated technique that requires trained technicians and expensive equipment that are 
not available in most developing regions.  
2.1.2. In Vivo Imaging 
Imaging systems can be grouped according to the energy used to derive the visual information  
(X-rays,  positrons,  photons  or  sound  waves),  the  spatial  resolution  (macroscopic,  mesoscopic  or 
microscopic) or the type of information obtained (anatomical, physiological, cellular or molecular). 
Unlike  classic  imaging  diagnosis  with  computed  tomography  (CT),  magnetic  resonance  imaging 
(MRI) or ultrasounds, nano-imaging  or molecular imaging includes techniques designed to  obtain 
molecular data to identify the causes of the disease in vivo rather than its eventual consequences. 
Nanotechnology has produced advances in imaging diagnosis, developing novel methods and increasing 
the resolution and sensitivity of existing techniques. Although these systems have emerging recently and Int. J. Mol. Sci. 2011, 12                       
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only  some  of  them  are  in  clinical  and  preclinical  use,  they  have  made  it  possible  to  study  human 
biochemical processes in different organs in vivo, opening up new horizons in instrumental diagnostic 
medicine.  These  systems  include  positron-emission  tomography  (PET),  single-photon-emission  
CT (SPECT), fluorescence reflectance imaging, fluorescence-mediated tomography (FMT), fiber-optic 
microscopy,  optical  frequency-domain  imaging,  bioluminescence  imaging,  laser-scanning  confocal 
microscopy and multiphoton microscopy [36]. 
Imaging diagnosis has gained importance over the years and is now an indispensable diagnostic tool 
for numerous diseases, including cancer, cardiovascular diseases and neurological syndromes.  The 
main benefits of molecular imaging for in vivo diagnosis lie in the early detection of disease and the 
monitoring  of  disease  stages,  e.g.,  in  cancer  metastasis  [37],  supporting  the  development  of 
individualized medicine and the real-time assessment of therapeutic and surgical efficacy. An ideal 
imaging  modality  should  be  non-invasive,  sensitive,  and  provide  objective  information  on  cell 
survival, function and localization. MRI, CT, PET) and SPECT are the most widely used and studied 
modalities in cancer patients [36,38,39] Overall, nuclear imaging by PET or SPECT offers greater 
sensitivity (>5 ×  10
3 cells) [40] but is limited by the lack of anatomical context [41], whereas MRI 
provides  accurate  anatomical  detail  but  no  data  on  cell  viability  and  shows  poor  sensitivity  
(>10
5 cells) [42]. Although none of these modalities is ideal, MRI is the preferred option for cellular 
tracking [39,43,44] By detecting proton relaxations in the presence of a magnetic field (1.5 Tesla [T]-3 
T for clinical imaging), it yields tomographic images with excellent soft tissue contrast and can locate 
the cells of interest in the context of the surrounding milieu (oedema or inflammation) [45,46] without 
the use of harmful ionizing radiations (the case with CT, PET or SPECT). In addition, MRI offers a 
longer tracking window in comparison to PET and SPECT, which are limited by the decay of the 
short-lived radioactive isotopes. 
In parallel to the development of imaging techniques, intense research has been fuelled by the need 
for  practical,  robust  and  highly  sensitive  and  selective  detection  agents  that  can  address  the 
deficiencies of conventional technologies. New contrast agents, used to increase the sensitivity and 
contrast  of  imaging  techniques  are  increasingly  complex  and  formed  by  synthetic  and  biological 
nanoparticles.  Nanoparticles  possess  certain  size-dependent  properties,  particularly  with  respect  to 
optical and magnetic parameters, which can be manipulated to achieve a detectable signal [47]. The 
primary event in most nanoparticle-based assays is the binding of a nanoparticle label or probe to the 
target biomolecule that will produce a measurable signal characteristic of the target biomolecule. A 
probe that is to function in a biological system must be water-soluble and stable and have minimal 
interaction with the surrounding environment. For fluorescence readouts, the probe should ideally have 
a high fluorescence quantum yield and minimal photobleaching rates in order to generate a detectable 
signal [48]. The most promising nanotechnologies for clinical diagnosis include quantum dots (QDs), 
gold nanoparticles and cantilevers, whose main features are summarized in Table 1.  Int. J. Mol. Sci. 2011, 12                       
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Table 1. Comparison of quantum dots (QDs), cantilevers and gold nanoparticles. 
Feature  QDs  Cantilevers  Gold nanoparticles 
Structure 
Semiconductor nanocrystals 
typically composed of a 
semiconductor core encapsulated 
by another semiconductor shell 
with a larger spectral band-gap; a 
third silica shell can be added for 
water solubility 
Nano-machined silicon or a 
piezoelectric 
material such as quartz similar 
to those used in atomic force 
microscopy 
Gold particles in the nanometre 
size domain; gold nanoshells 
consist of concentric sphere 
nanoparticles with a dielectric 
core (typically gold sulfide or 
silica) surrounded by a thin gold 
shell 
Size  2–10 nm  Nanoscale 
2–150 nm 
(changes in optical properties as 
a function of size) 
Diagnostic 
applications 
- In vitro diagnosis: 
immunohistochemistry, infectious 
agent detection, 
fluoroimmunoassays, 
immunoassays, intracellular 
imaging and tissue imaging. 
- In vivo imaging 
DNA and protein (various 
biomarkers) detection and 
quantification. 
Detection of DNA and proteins 
(including antibodies) 
Method for 
detecting 
Fluorometry and several types of 
microscopy, such as
 fluorescence, 
confocal, total internal reflection, 
wide-field
 epifluorescence, atomic 
force, and multiphoton 
microscopy 
Operate either statically, by 
measuring absolute cantilever 
deflection, or dynamically, by 
measuring resonance 
frequency shifts 
Surface plasmon resonance 
microscopy. Gold particles 
coated
 with silver have strong 
light-scattering properties
 and 
can easily be detected by 
standard dark-field microscopy
 
with white light illumination 
Advantage 
- Their optical tunability, 
resistance to photobleaching, 
excitation
 of various QDs by a 
single wavelength of light (for 
multiplexing),
 narrow emission 
band, and exceptional stability of 
optical properties after 
conjugation to a biomolecule. 
- They do not need lasers for 
excitation. 
- The instrumentation needed for 
detection is simple. 
- Their sensitivity, 
compatibility with silicon 
technology, and capacity for 
microfluidic integration. 
 
- Good potential for high 
throughput protein screening 
Their optical properties, useful 
for imaging and photothermal 
therapy. 
Their surfaces, functionalized 
using various well-characterized 
chemical moieties (thiols, 
disulfides, amines) 
Toxicity 
Risk of leakage of toxic core 
semiconductor materials into host 
system or into the environment on 
disposal 
No particular toxicity 
concerns 
No particular toxicity concerns 
 Int. J. Mol. Sci. 2011, 12                       
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2.2. Drug Delivery 
One of the most important nanotechnology applications developed over the past decade have been 
nanovehicles, nanoscale compounds used as a therapeutic tool and designed to specifically accumulate 
in the sites of the body where they are needed in order to improve pharmacotherapeutic outcomes. The 
main objective of this application is to increase therapeutic effectiveness while obtaining lower toxicity 
rates. Hence, nanodrugs and nanodiagnostics have been developed to increase bioavailability profiles, 
enabling the administration of lower doses and thereby minimizing the adverse reactions found with 
conventional  drugs  in  clinical  practices  and  increasing  the  quality  of  patient  health  [49].  Table  2 
compiles some drugs using nanocarriers and their route of administration. 
Table 2. Some drugs using nanocarriers and their administration routes. 
Compounds  Nanocarrier  Application 
CPX-1 irinotecan  Liposome  Systemic 
DNA (gene therapy)  Solid lipid nanoparticles  Systemic 
Cancer vaccine 
Immunostimulatory acid-degradable 
microparticles 
Subcutaneously 
Camptothecin  Polymeric nanoparticles  Systemic 
Tamoxifen citrate  Solid lipid nanoparticles  Systemic 
Pilocarpine hydrochloride  Polymeric nanoparticles  Systemic 
Clotrimazole 
Solid lipid nanoparticles and nanostructured 
lipid carriers 
Topical 
Clozapine  Solid lipid nanoparticles  Systemic 
Coenzyme Q 10  Solid lipid nanoparticles  Topical 
Titanium dioxide  Solid lipid nanoparticles  Topical 
5-Fluorouracil  Nanostructured lipid carriers  Systemic 
Ibuprofen  Solid lipid nanoparticles  Topical 
Insulin  Solid lipid nanoparticles  Systemic 
Isotretinoin  Solid lipid nanoparticles  Systemic 
Ketoconazole  Solid lipid nanoparticles  Topical 
Mifepristone  Solid lipid nanoparticles  Systemic 
N,N-Diethyltoluamide 
(DEET) 
Solid lipid nanoparticles  Topical 
N-dodecyl-ferulate  Solid lipid nanoparticles  Systemic 
Oxybenzone  Solid lipid nanoparticles  Topical 
Clobetasol propionate  Nanostructured lipid carriers  Systemic 
Retinoids  Solid lipid nanoparticles  Topical 
Triptolide  Solid lipid nanoparticles  Systemic 
Vitamin A  Solid lipid nanoparticles  Topical 
MCC465 doxorubicin  mAb-liposome  Systemic 
NC-6004 cisplatin  Micelle  Systemic 
NK105 paclitaxel  Micelle  Systemic 
NK911 doxorubicin  Micelle  Systemic 
PK1 doxorubicin  HPMA copolymer   
SP1049C doxorubicin  Micelle  Systemic Int. J. Mol. Sci. 2011, 12                       
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Table 2. Cont. 
Compounds  Nanocarrier  Application 
Etoposide  Nanostructured lipid carriers  Systemic 
Docetaxel  Nanostructured lipid carriers  Systemic 
Paclitaxel  Nanostructured lipid carriers  Orally 
Paclitaxel  Polymeric nanoparticles  Subcutaneously 
In the field of cancer therapy there are a lot of clinical applications based on nanotechnologies, with 
a major development in drug delivery systems. The reason for the rise in nanotechnology applications 
in medicine is the prospect of improving effectiveness by the biological targeting of drugs in current 
clinical use [50]. In cancer treatments, nanoparticles are usually administered by intravenous injection, 
travelling  in  the  blood  stream  and  pass ing  through  biological  barriers  (cell  membranes)  of  the 
organism in order to reach  and activate their molecular targets [51]. One of the main objectives of 
nanotechnology is overcome the shortcomings of classical chemotherapy, including the multiple drug 
resistance mechanisms that make this treatment ineffective in a high percentage of cancer cases. The 
other problem of conventional anticancer therapies is the non-specific action of the drugs, leading them 
to damage both tumor and non-tumor cells in a state of division. 
Nanoparticles can overcome the side effects of conventional therapies by the following means: 
(1) sustaining drug release over time;  (2) so-called ―passive enhanced  permeability‖, targeting  the 
effect to tumor tissue; (3) targeting the cell surface with the use of ligands related to endosomal uptake 
and membrane disruption; (4) permitting release of the drug in the cell cytoplasm; and (5) protecting 
the  drug  from  enzymatic  degradation  [52,53].  The  main  goals  of  drug  delivery  design  are:  (i)  to 
decrease the side effects of conventional therapy by decreasing drug concentration in normal tissues; 
(ii) to enhance the pharmacokinetics and pharmacodynamics profiles; (iii) to allow intravenous drug 
administration by increasing drug solubility; (iv) to minimise drug loss in transit and maximize drug 
concentration in the tumor; (v) to improve drug stability by avoiding drug degradation; (vi) to achieve 
optimal  cellular  uptake  and  intracellular  delivery;  and  (vii)  to  ensure  biocompatibility  and 
biodegradability [54].  
Alternative methods have been developed to increase the effectiveness of drug delivery using the 
passive or active targeting capacities of nanovehicles. The passive targeting form of drug delivery 
consists of transporting nanoparticles through leaky tumor capillary fenestrations within the tumor 
mass to reach cells by convection or passive diffusion. Convection is related to the movement of 
molecules through organic fluids and is the predominant transport mode for a high percentage of 
molecules across large pores. However, compounds with a low molecular weight (e.g., oxygen) are 
most  frequently  transported  by  diffusion,  in  which  molecules  cross  the  cell  membrane  along  a 
concentration gradient, with no energy cost to the cell. In fact, convection through the tumor mass is 
poor, due to interstitial hypertension; therefore, diffusion is the main type of drug transport used, 
accumulating nanoparticles with drug by the so-called Enhanced Permeability and Retention (EPR) 
effect. Nanoparticles are able to achieve an optimal EPR effect if they can evade the immune response, 
and they remain highly stable in  the blood stream  until  reaching  the  tumor. The EPR effect  is  a 
physiological process based on the capacity of long-circulating nanoparticles to penetrate through the Int. J. Mol. Sci. 2011, 12                       
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leaky tumor-formed vasculature and degrade within the tumor, releasing the drug and achieving a local 
concentration in solid tumors that is several-fold higher than that obtained with free drugs [55]. 
Very high local concentrations of drug-loaded nanoparticles have been obtained within tumors, 
from  10-  to  50-fold  higher  in  comparison  to  normal  tissues  in  a  time  period  of  1–2  days.  The 
achievement of these drug concentrations in the tumor requires nanoparticles to possess the following 
characteristics: (a) nanoparticle size between 10 and 100 nm; (b) a neutral or anionic nanoparticle 
surface charge to prevent elimination by the kidneys; and (c) the ability to avoid opsonization and 
phagocytosis, which destroy foreign material via the reticuloendothelial system [54,56]. 
Active targeting using nanoparticles as the delivery system allows a specific area of the body to be 
targeted, avoiding one of the drawbacks of current chemotherapy, i.e., toxic effects in non-malignant 
organs [57]. Studies are being carried out on the attachment of targeting ligands on the nanoparticle 
surface, enabling specific binding of the nanoparticle to receptors on the tumor cell surface. Ligands 
that bind to specific overexpressed receptors are selected. The types of ligand used include antibodies, 
antibody fragments or non-antibody (peptidic) ligands. Over the past few years, considerable interest 
has developed in the numerous antigens present on tumor cells. For instance, HER2 receptor has been 
proposed as a therapeutic target. HER2 gene, also known as c-erbB2 and neu, encodes a 185-kDa 
transmembrane glycoprotein receptor that belongs to the ErbB family of growth factor receptors with 
intrinsic tyrosine kinase activity, whose members exist in homodimer and heterodimer form when 
activated [58]. Trastuzumab is a humanized antibody designed to specifically recognize the HER-2 
receptor and was approved by the FDA in 1998 for the treatment of metastatic breast cancer. Different 
studies have shown that normal cells can express moderate amounts of HER2 target antigen, while it is 
overexpressed in tumors in certain patients, and this difference between healthy tissues and tumors 
allows the effective use of this antibody in patients [59].  
Fibroblast growth factor receptors (FGFRs) have also become potential targets for drug delivery 
and cancer therapy. Fibroblast growth factors (FGFs) are small peptide growth factors that play an 
important role in tumor growth and angiogenesis because of their high affinity to heparin. FGFRs are 
upregulated versus normal tissues in numerous tumor cells and tumor neovasculature in situ [60]. One 
candidate as a targeting ligand for tumor cells is the peptide KRTGQYKLC (bFGFp), which could 
interact with FGFR1 by binding to bFGF. The epidermal growth factor receptor (EGFR) is a receptor 
tyrosine kinase over-expressed on many human cancer cells surface, making it a target for anticancer 
drug  delivery.  Liposomes  targeting  this  receptor  promoted  the  effective  intracellular  delivery  of 
doxorubicin to tumor cells, yielding superior anti-tumor effects in different in vivo assays. In previous 
studies, the peptide GE11 was identified as a novel ligand with high affinity towards EGFR and proved 
effective to mediate targeted liposome delivery to EGFR-positive tumors in vivo [61]. Investigations 
are ongoing into drug delivery systems based on nanoparticles with different geometry, compositions 
and surface modifications (Figure 2). They are providing researchers with an enormous collection of 
nanoparticles with promising applications [62]. 
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Figure 2. Some drug delivery systems. 
 
2.2.1. Micelles  
A micelle is an aggregate of amphiphilic surfactant molecules spontaneously created on immersion 
in water, usually forming spherical vesicles. They contain a hydrophobic core in which hydrophobic 
substances, such as pharmacological compounds, can be introduced for release in different parts of the 
organism.  A  micelle  typically  comprises  a  hydrophilic  or  polar  charged  ―head‖  group  and  a 
hydrophobic  ―tail‖,  normally  composed  of  a  hydrocarbonated  portion  of  long  fatty  acids.  The 
characteristics of the surfactants that make up the micelle determine its size [63]. 
2.2.2. Nanoemulsions 
Nanosized emulsions are composed of a mixture of two-phase insoluble liquids, in which vesicles 
in the dispersed phase are surrounded by the continuous phase. Different types of surfactants are used 
to  stabilize  the  emulsion,  preventing  the  dispersed  phase  from  coalescing  into  a  macroscopic  
phase [64]. Many emulsions used in drug delivery systems can be formulated on a nanosize scale. In 
these cases, the aqueous phase conform the continuous phase, and the drug is often carried in (or is 
itself)  the  non-aqueous  liquid  phase  of  the  emulsion.  Generally,  the  surfactant  molecules  used  to 
stabilize micelles are the same as those forming the structural part of the nanoemulsions [65]. Int. J. Mol. Sci. 2011, 12                       
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2.2.3. Solid Nanoparticles 
This structure presents different characteristic features such as: (a) the material present in the centre 
of the particle forms a solid core at least at room temperature; (b) Solid nanoparticles not necessarily 
present in a spherical form. The geometry may change, presenting angular forms. This characteristic is 
particularly visible if the nanoparticle consists of crystals of a protein or another therapeutic agent. To 
avoid flocculation a surfactant is usually required to stabilize the nanoparticle [65]. 
2.2.4. Dendrimers 
These  are  usually  regularly-branched  three-dimensional  structures  with  a  treelike  form  and  a 
molecule as the central core. Branching units emerge from the central molecule by polymerization or 
are synthesized from the periphery and terminate at the central molecule. Branch lengths have steric 
limitations  and  dendrimer  forms  are  sphere-shaped,  with  low  molecular  size  but  high  molecular 
weight. These structures are used to transport drugs in two ways: (a) by attaching drug molecules to 
functional groups on the dendrimer surface; or (b) by enclosing the drugs in the dendritic channels 
within the sphere. The well-defined structure, size monodispersity, surface functionalization capability 
and stability of these nanoparticles make them a promising vehicle system for various agents (e.g., 
genes and anticancer drugs) by complexation or encapsulation [66,67]. One example is the formation 
of dendrimers with polymers such as polyamidoamine (PAMAM), which confer stability, availability 
and tolerability. The drug is contained in a central cavity and can be entrapped in channels between 
dendrons [23]. 
2.2.5. Liposomes 
The effectiveness of liposomes as drug vehicles is related to their pharmokinetics and depends on 
the physicochemical conditions, e.g., size, surface charge, membrane lipid packing, steric stabilization, 
dose, and administration route [68]. A major advantage of liposomes is their long persistence in the 
blood,  favoring  the  delivery  of  their  contents  to  target  tissues.  Liposomes  with  diameters  of  
100–300  µm   accumulate  around  tumors  and  are  not  subject  to  rapid  clearance  by  the 
reticuloendothelial  system  [69].  Liposomes  are  vesicular  nanostructures  formed  by  a  lipid  bilayer 
composed  of  phospholipid  and  cholesterol  molecules  (structural  components  of  cell  membranes) 
characterized  by  extended,  two-dimensional  and  clearly  separated  hydrophilic  and  hydrophobic 
regions. The hydrophilic portions of bilayer lipids are directed towards aqueous phases (external and 
internal), whereas the hydrophobic portions of both lipid layers are directed towards one another, 
forming an internal hydrophilic compartment that can encapsulate water-soluble drugs [70]. Actually 
there is a type of liposome well studied in clinical, the pegylated liposomes, which forms a water shell 
on the liposomal surface and provides a steric barrier to the liposomes for avoiding interactions with 
plasma proteins, resulting in escape from trapping by the reticuloendothelial system [71]. One example 
is liposomal-encapsulated doxorubicin, which has an elimination half-life of 55 h in comparison to 
only 0.2 h for doxorubicin in  free form.  The drugs  are solubilized and protected from  enzymatic 
degradation and inactivation either by physical entrapment within the nanoparticle or by conjugation Int. J. Mol. Sci. 2011, 12                       
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with  constituent  components.  Encapsulation  into  the  liposomal  carrier  also  causes  a  significant 
reduction in the most significant adverse side effect of doxorubicin, such as cardiotoxicity [72]. 
2.3. Regenerative Medicine 
Tissue engineering brings together principles and innovations from engineering and the life sciences 
for  the  improvement,  repair  or  replacement  of  tissue/organ  function.  Since  its  inception,  this 
multidisciplinary field has been governed by the generic concept of combining cell, scaffold (artificial 
extracellular matrix) and bioreactor technologies in the design and fabrication of neo-tissues/organs [73]. 
Every  tissue  or  organ  in  our  body  is  composed  of  parenchymal  cells  (functional  cells)  and 
mesenchymal  cells  (support  cells)  contained  within  an  extracellular  matrix  to  form  a 
microenvironment, and these microenvironments collectively form our tissues and organs. In terms of 
the development and maintenance of tissues and organs, our body is the ―bioreactor‖, exposing the 
microenvironment of the cell and extracellular matrix to biomechanical forces and biochemical signals. 
The ultimate goal is to enable the body (cellular components) to heal itself by introducing a tissue 
engineered scaffold that the body recognizes as ―self‖ and uses to regenerate ―neo-native‖ functional 
tissues [74]. Furthermore, the demand for organs for transplantation far exceeds the supply, and the 
construction of organs by regenerative therapy has been presented as a promising option to address this 
deficit. Nanotechnology has the potential to provide instruments that can accelerate progress in the 
engineering  of  organs  [75].  Achievement  of  the  more  ambitious  goals  of  regenerative  medicine 
requires control over the underlying nanostructures of the cell and extracellular matrix. Cells, typically 
microns in diameter, are composed of numerous nanosized components that all work together to create 
a highly organized, self-regulating machine. Cell-based therapies, especially those based on stem cells, 
have generated considerable excitement in the media and scientific communities and are among the 
most promising and active areas of research in regenerative medicine [76]. The pace of research could 
be accelerated by the creation of multi-functional tools to improve the monitoring and modification of 
cell behavior. While nanomedicine is primarily focused on cancer-related research, the application of 
nanotechnology has considerable potential in cell-based therapies for regenerative medicine, e.g., in 
localizing, recruiting and labeling stem cells to begin the regeneration process [75]. 
3. Conclusions 
Nanotechnology  is  an  emerging  interdisciplinary  field  that  combines  biology,  chemistry  and 
engineering. It is expected to lead to major advances towards individualized medicine, improving the 
sensitivity and specificity of existing techniques to discover and detect biomarkers and developing 
novel  nanodiagnostic  instruments.  This  would  allow  earlier  and  more  personalized  diagnosis  and 
therapy,  improving  the  effectiveness  of  drug  treatments  and  reducing  side  effects.  In  addition, 
nanoparticles  are  a  promising  platform  technology  for  the  synthesis  of  molecular-specific  
contrast agents. Int. J. Mol. Sci. 2011, 12                       
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